The classical goals of haemophilia A treatment are to prevent bleeds, minimise the risk of
long-term complications associated with joint damage, and improve quality of life by …

Despite effective factor replacement and various treatment schedules, there remain several
challenges and unmet needs in the prophylactic treatment of hemophilia limiting its adoption …

The physiotherapist plays an essential role for people with haemophilia, an inherited
bleeding disease responsible for musculoskeletal complications. Yet, with the advent of new …

Background Despite the advantages of prophylactic treatment for hemophilia, patients tend
to discontinue or not adhere to it because of several challenges such as long-term use, high …

Background Real‐life data on pharmacokinetics of factor (F) VIII/IX concentrates, especially
extended half‐life (EHL), concentrates in large cohorts of persons with hemophilia are …

Replacement therapy with concentrates of factor VIII or IX remains the gold standard for
severe haemophilia management. The recent development of clotting factor products with …

Prophylactic therapy with exogenous clotting factor concentrates in haemophilia A and B
aims to achieve levels of circulating FVIII or FIX that are adequate for the prevention or …

Abstract BAY 94-9027 is an extended-half-life, recombinant factor VIII (rFVIII) product
conjugated with a 60-kDa branched polyethylene glycol (PEG) molecule indicated for use in …

Background Performing individual pharmacokinetics (PK) studies in clinical practice can be
simplified by adopting population PK-based profiling on limited post-infusion samples. The …

The purpose of this narrative review was to provide an overview that allows readers to
improve their understanding of hemophilia A, which is considered a genetic disease with a …